DAB/IL2 is FDA-approved for the treatment of patients with persistent or recurrent cutaneous T cell lymphoma (CTCL) whose malignant cells express CD25. Here, IL2 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.